Flagship Pioneering, LLC Long-Term Concentrated

CIK: 0001400240 · Show all filings

Period: Q4 2016 (← Previous) (Next →)

Filing Date: Feb 13, 2017

Total Value ($000): $307,344 (100.0% shares, 0.0% debt)

Holdings (7)

— SERES THERAPEUTICS INC 40.9%

Value ($000) $125,560 Shares 12,682,876 Est. Cost $12.29 Unrealized —

— SYROS PHARMACEUTICALS INC 19.0%

Value ($000) $58,449 Shares 4,806,656 Est. Cost $13.87 Unrealized —

EDIT EDITAS MEDICINE INC 18.2%

Value ($000) $56,080 Shares 3,455,316 Est. Cost $20.49 Unrealized -25.9%

AGIO AGIOS PHARMACEUTICALS INC 13.1%

Value ($000) $40,285 Shares 965,369 Est. Cost $43.55 Unrealized +20.5%

— SELECTA BIOSCIENCES INC 4.6%

Value ($000) $14,181 Shares 826,862 Est. Cost $14.25 Unrealized —

— T2 BIOSYSTEMS INC 3.3%

Value ($000) $10,260 Shares 1,950,583 Est. Cost $7.24 Unrealized —

— ELEVEN BIOTHERAPEUTICS INC 0.8%

Value ($000) $2,529 Shares 1,324,018 Est. Cost $2.80 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	SERES THERAPEUTICS INC	12,682,876	$125,560	40.9%	$12.29	—	COM	81750R102
—	SYROS PHARMACEUTICALS INC	4,806,656	$58,449	19.0%	$13.87	—	COM	87184Q107
EDIT	EDITAS MEDICINE INC	3,455,316	$56,080	18.2%	$20.49	-25.9%	COM	28106W103
AGIO	AGIOS PHARMACEUTICALS INC	965,369	$40,285	13.1%	$43.55	+20.5%	COM	00847X104
—	SELECTA BIOSCIENCES INC	826,862	$14,181	4.6%	$14.25	—	COM	816212104
—	T2 BIOSYSTEMS INC	1,950,583	$10,260	3.3%	$7.24	—	COM	89853L104
—	ELEVEN BIOTHERAPEUTICS INC	1,324,018	$2,529	0.8%	$2.80	—	COM	286221106